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Background. Onchocerca volvulus and lymphatic ﬁlariae, causing river blindness and elephantiasis, depend on
endosymbiotic Wolbachia bacteria for growth, development, fertility, and survival. Clinical trials have shown that
doxycycline treatment eliminates Wolbachia, causing long-term sterilization of adult female ﬁlariae and effecting
potent macroﬁlaricidal activity. The continual reinfection by drug-naive worms that occurs in these trial settings
dilutes observable anti-Wolbachia and antiﬁlarial effects, making it difﬁcult to estimate therapeutic efﬁcacy and com-
pare different doxycycline regimens, evaluated at different times after treatment.
Methods. Ameta-analytical modeling framework is developed to link all usable data collected from clinical trials
measuring theWolbachia status and viability of individual female adult worms collected at various times after treat-
ment with 4, 5, or 6 weeks of daily 100 or 200 mg oral doxycycline. The framework is used to estimate efﬁcacy
parameters that are not directly measurable as trial outcomes.
Results. The estimated efﬁcacy of doxycycline (the maximum proportional reduction in the percentage of adult
female O. volvulus positive for Wolbachia) is 91%–94% on average, irrespective of the treatment regimen. Efﬁcacy is
>95% in the majority of trial participants. The life span ofWolbachia-depleted worms is reduced by 70%–80%, from
approximately 10 years to 2–3 years.
Conclusions. The efﬁcacy parameters are pertinent to the prospects of using doxycycline on a “test and treat”
basis for onchocerciasis control and conﬁrm doxycycline as a potent macroﬁlaricidal therapy. The modeling
approach is more generally relevant to the design and evaluation of clinical trials for antiﬁlarial drugs conducted
in endemic settings.
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Most ﬁlarial parasites of humans depend on endosym-
bioticWolbachia bacteria for growth, development, fer-
tility, and survival [1]. Clinical trials have shown that
eliminating Wolbachia from Onchocerca volvulus and
Wuchereria bancrofti—the etiological agents of oncho-
cerciasis (river blindness) and (bancroftian) lymphatic
ﬁlariasis (elephantiasis), respectively—with a course of
oral doxycycline permanently sterilizes female worms
and reduces the adult worm longevity, inducing potent
macroﬁlaricidal activity (ie, the killing of adult [macro]
ﬁlariae). These properties are superior to those of other
currently used antiﬁlarial drugs—diethylcarbamazine,
ivermectin, and albendazole—which predominantly
act against the microﬁlarial progeny of female worms,
having somewhat limited activity against adults [2].
This particularly applies to onchocerciasis, for which
only ivermectin is used for mass drug administration.
Clinical trials of anti-Wolbachia therapy have typical-
ly evaluated antiﬁlarial activity using immunohistolog-
ical, molecular, and morphological criteria, measured at
various times after treatment. In lymphatic ﬁlariasis,
loss of female fertility is demonstrated through absence
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of microﬁlaremia (microﬁlariae in the blood), whereas worm vi-
ability is assessed by loss of ultrasonographic detection of “ﬁlarial
dance sign” (a pathognomonic type of movement by live adult
worms within worm nests) and reduction in circulating ﬁlarial
antigenemia [3]. In onchocerciasis, worm fertility and viability
are determined by immunohistological and morphological exam-
ination of O. volvulus macroﬁlariae within subcutaneous nodules
excised from trial participants [4]. Female fertility is monitored by
reduced microﬁlaridermia (microﬁlariae in the skin) [5].
The dynamics of the antiﬁlarial outcomes induced by doxycy-
cline are protracted because of the indirect mode of action of anti-
Wolbachia therapy on parasites’ vital processes. Doxycycline elicits
a gradual yet sustained reduction in microﬁlaridermia, not because
it killsO. volvulusmicroﬁlariae directly, but because the microﬁlar-
ial population is not replenished by (sterilized) female worms, with
skin microﬁlariae declining through natural attrition. Adult worms
suffer a similar “slow-kill” effect. InO. volvulus, an increased abun-
dance of dead worms is observed approximately 2 years after the
start of doxycycline therapy. In W. bancrofti, an increase in the
proportion of patients without detectable worm nests (loss of ﬁlar-
ial dance sign) is observed between 12 and 18 months [6].
The slow antiﬁlarial activity of anti-Wolbachia therapy con-
fers an excellent safety proﬁle by avoiding inﬂammatory reac-
tions associated with rapid killing of micro- or macroﬁlariae
[2]. However, it also complicates interpretation of antiﬁlarial
outcomes; during a long follow-up period, trial participants,
who continue to live in endemic areas with ongoing transmis-
sion, become reinfected with worms harboring a full comple-
ment of Wolbachia. This dilutes the apparent antiﬁlarial
efﬁcacy of a treatment regimen [7]. Furthermore, the intrinsic
time dependency of antiﬁlarial activity makes it difﬁcult to
compare outcomes measured after different follow-up periods,
in different epidemiological settings, from patients treated for
different durations with different doses.
Modeling the interacting temporal dynamics of Wolbachia de-
pletion, antiﬁlarial activity and parasite infection can resolve these
issues by providing a framework with which to link data from
clinical trials that used different treatment regimens and follow-
up periods. Taking this approach, we (1) estimate and compare
the efﬁcacy of different treatment regimens in eliminatingWolba-
chia from female worms, and (2) quantify the ensuing macroﬁlar-
icidal activity in terms of a reduced adult life span.We discuss our
results in the context of alternative or complementary interven-
tions required to achieve proposed control and elimination goals.
METHODS
Data
The data originate from 1 randomized, placebo-controlled trial
[8] and 2 open (nonrandomized, untreated controls) trials
[9, 10] on the effects of doxycycline on O. volvulus, the only
ﬁeld trials to have collected useable data on individual adult
O. volvulus (Supplementary Methods, Systematic Review). Par-
ticipants infected with O. volvulus micro- and macroﬁlariae re-
ceived 4, 5, or 6 weeks of directly observed 100 or 200 mg oral
doxycycline (or placebo) daily and were followed up on multiple
occasions to have operable onchocercomas extirpated. Partici-
pants not completing the course of treatment were not followed
up (Supplementary Methods, Participant Compliance and Fol-
low-up). Each O. volvulus was categorized as dead or alive, and
conditional on being alive, Wolbachia positive or Wolbachia
negative by morphological and immunohistological analyses.
The data are summarized in Table 1 and Supplementary Table 1.
Some participants received ivermectin either as part of study
protocols or prior to receiving doxycycline (mainly from mass
drug administration programs [8, 9, 10]). Such data are not in-
cluded in the analysis because ivermectin does not affect Wol-
bachia [8, 9] nor (at recommended regimens [11]) the longevity
of adult O. volvulus.
Population Dynamics Model
Numbers of larval and live and dead adult O. volvulus are mod-
eled by a system of ordinary differential equations, represented
schematically in Figure 1. Participants are infected with L3 lar-
vae at a constant rate, the force of infection (the proportion
of trial participants relative to the whole population is too
small to affect the intensity of transmission and the impact of
possible seasonal ﬂuctuations in ﬂy biting is negligible; Supple-
mentary Analyses, Seasonality in the Force of Infection). The
larval state is unobserved in the data but captures the approxi-
mate 2-year prepatent period of O. volvulus [12]. Live adults are
divided into Wolbachia-positive, Wolbachia-depleted, and
Wolbachia-negative states. The rate of progression between
Wolbachia-positive and Wolbachia-depleted states is governed
by the modeled concentration of doxycycline. Wolbachia-
depleted worms pass into the Wolbachia-negative state at a
constant rate (independent of the concentration of doxycy-
cline), where they become immunohistologically detectable as
Wolbachia-negative. The Wolbachia-depleted state is unob-
served, but its inclusion permits the protracted decline in Wol-
bachia-positive worms while allowing for the possibility that
some treatment regimens were suboptimal and precipitated sys-
tematically lower numbers of Wolbachia-negative worms. Mac-
roﬁlaricidal activity is embodied by an excess mortality of
Wolbachia-depleted and Wolbachia-negative worms such that
their expected life span can be shorter than the 8 to 12 years
[13] of worms with a full complement ofWolbachia. Prophylac-
tic activity of doxycycline is modeled by an excess mortality of
immature worms and inhibition of their progression to adults,
ensuring that larvae cannot establish as adults during treatment,
consistent with experimental observations on the effects of tet-
racyclines on ﬁlarial parasites of rodents [14, 15].
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Doxycycline Pharmacokinetics and Pharmacodynamics
A pharmacokinetic (PK) and pharmacodynamic (PD) submo-
del relates doxycycline dose and concentration to ensuing anti-
Wolbachia and antiﬁlarial effects (Supplementary Methods,
Pharmacokinetics Model and Pharmacodynamics Model).
Participants’ blood plasma concentrations of doxycycline are
modeled using a 2-compartment PK model with treatment du-
ration 4, 5, or 6 weeks, dose of 100 or 200 mg daily, and pub-
lished PK/PD parameter estimates (Supplementary Table 2).
Doxycycline is assumed to exhibit binary concentration-
Table 1. Summary of Nodulectomy Data Collated From 3 Clinical Trials on the Effects of Doxycycline on Female Onchocerca volvulus
Regimen
Follow-up, mo
After Treatment Participants Extirpated Nodules
Female Worms by
Wolbachia Status
Dead Female WormsDuration, wk Dose, mg, per day Positive Negative
4 200 20–39a 14 72 17 42 62
5 100 20–27 20 96 20 63 79
6 100 2–18 62 217 72 321 91
6 200 6–39a 18 115 27 71 109
6 Placebo 5.5–27 23 103 150 10 46
Untreated NA NA 45 142 236 8 44
Abbreviation: NA, not applicable.
a Data from patients nodulectomized at the 39-month follow-up time were not presented as part of the main analysis in the original study [8].
Figure 1. Schematic representation of the model describing the dynamics of Wolbachia depletion from adult ﬁlariae coupled to the ensuing antiﬁlarial
effects. The variables Li(t ), Wi
+(t ), Wi
± (t ), Wi
–(t ), and Di(t ) denote, respectively, the mean number of infective (L3) larvae, and Wolbachia-positive, Wol-
bachia-depleted, Wolbachia-negative, and adult dead worms in trial participants given drug regimen i. The smaller gray squares in (A) indicate the positions
of latent compartments used to assess model structural uncertainty on parameter estimates. These latent compartments are omitted from (B ) and (C ) for
clarity. Temporal dependence in certain per worm rate parameters [eg, δi(t )] is governed by whether the average blood plasma concentration of doxycycline
in participants given drug regimen i, Ci (t ), is greater than the minimum inhibitory concentration (MIC) against Wolbachia (Supplementary Methods, Phar-
macokinetic Model). Infective, L3 larvae are acquired at rate Λ, die at (per capita) rate σi(t ), and progress toward Wolbachia-positive adult worms at rate
γi(t ). When the concentration of doxycycline is above the MIC, σi(t ) = σ0 + σ1 and γi(t ) = 0 (B ). Below the MIC, σi(t ) = σ0 and γi(t ) = γ0. Wolbachia-positive
worms die at rate µ0, becoming immunohistologically or morphologically identiﬁable as dead, before being resorbed at rate η. Depletion of Wolbachia
occurs at rate δi(t ) = δ1 while the concentration of doxycycline is greater than the MIC; no depletion occurs otherwise [δi(t ) = 0]. Wolbachia-depleted
worms become immunohistologically observable as Wolbachia negative at rate ζ. Both Wolbachia-depleted and Wolbachia-negative worms incur a higher
mortality rate than their Wolbachia-positive counterparts, µ0 + µ1 (the combination of background mortality and doxycycline-induced, excess mortality).
Doxycycline Therapy for Onchocerciasis • CID • 3
dependent activity or inactivity, depending on whether the con-
centration is above or below the minimum inhibitory concentra-
tion, respectively (Supplementary Methods, Pharmacodynamics
Model), reﬂecting the primarily bacteriostatic action of tetracy-
cline antibiotics [16].
Statistical Model
The dynamic models deﬁne means in groups of individuals tak-
ing a particular drug regimen. However, the available data are
individual-based and longitudinal and, consequently, observa-
tions from the same individual at different times (repeated mea-
sures) are not independent. Dependence arises from variation
unaccounted for by the measured covariates, including nonspe-
ciﬁc PK/PD or parasite population dynamic variation. The
mean-based dynamic model is therefore augmented with indi-
vidual-speciﬁc random effects, permitting the modeled pro-
portion of live worms and (live) Wolbachia-positive worms to
vary among participants (Supplementary Methods, Statistical
Model). This accounts for correlation among repeated measures
and suitably inﬂates estimates of parameter uncertainty. State
probabilities, rather than absolute numbers, are modeled to
“normalize” the data, nullifying the effects of variation in the
force of infection among participants.
Parameter Inference
Inference is conducted in a Bayesian framework [17], integrat-
ing parameter uncertainties into estimated parameter posterior
distributions (posteriors) using bespoke Markov chain Monte
Carlo techniques [18, 19] (Supplementary Methods, Parameter
Inference). Parameters with prior information available in the
literature (9 in total) are assigned informative uniform prior
distributions (priors) with bounds deﬁned by the range of pub-
lished estimates (Supplementary Table 2). Parameters without
prior information (7 in total as listed in Table 2, excepting µ0)
are assigned uninformative priors (Supplementary Table 2 and
Supplementary Figure 1). The adequacy of the model ﬁt to the
data is conﬁrmed by inspection of standardized residuals (Sup-
plementary Analyses, Diagnostic Checks).
Model Structural Uncertainty
The “one-state, one-compartment” structural conﬁguration im-
plicitly assumes an exponential distribution of transition times
between contiguous states. This assumption can affect parame-
ter estimates [20] and is explored by reconﬁguring the model
into a “one-state, multiple-compartment” structure using “la-
tent” compartments (Figure 1). Details are given in Supplemen-
tary Analyses, Model Structural Uncertainty.
RESULTS
Dynamics of Wolbachia Depletion
The observed and estimated percentages ofWolbachia-positive O.
volvulus with time after the start of doxycycline treatment or
matching placebo are illustrated in Figure 2A. Parameter posterior
estimates are summarized in Table 2. From the Wolbachia-
depleted state, it takes, on average, 70–87 days before theWolbachia
populations are cleared and worms are detected as Wolbachia
negative. This drives the protracted decline in the percentage
of Wolbachia-positive worms, which has a nadir approximately
9.5 months after the start of doxycycline treatment.
The rate of depletion from the Wolbachia-positive to the
Wolbachia-depleted state is unidentiﬁable (Supplementary Fig-
ure 1), suggesting that treatment regimens are equally effective
in depleting Wolbachia; none of the regimens are either too
short, or given at insufﬁcient dose, to elicit systematically
lower percentages of Wolbachia-positive worms.
The dynamics of Wolbachia depletion followed by clearance
indicate that (1) the time taken for Wolbachia populations to
become eventually extinct is much longer than the time taken
Table 2. Parameter Posteriors Estimated by Fitting the Dynamic Model to Doxycycline Clinical Trial Data on the Wolbachia Status and
Vitality of Female Onchocerca volvulus From 182 Participants
Parameter Definition
Posterior Meana
(95% BCI)
Range of
Posterior Meanb Units
1/(µ0 + µ1) Life expectancy of Wolbachia-depleted adult worms 2.1 (1.7–2.7) 2.1–3.0 Years
1/ζ Average clearance time of depleted Wolbachia populations from adult worms 70 (56–85) 70–87 Days
1/η Average resorption time of dead adult worms 1.9 (1.4–2.5) 1.8–1.9 Years
π Probability that a worm is correctly identified as Wolbachia positive 0.97 (0.95–0.99) 0.97–0.97 None
υ1 Inverse variance (precision) among individual hosts in the proportion of live
female worms
5.1 (3.0–8.7) 5.1–5.6 None
υ2 Inverse variance (precision) among individual hosts in the proportion of
Wolbachia-positive female worms
4.2 (1.8–9.5) 2.9–4.8 None
Abbreviation: BCI, Bayesian credible interval.
a Reported to 2 significant figures.
b Range of posterior means calculated using different model structural configurations.
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for doxycycline to push the bacteria populations into terminal
decline, and/or (2) it takes a long time for dead Wolbachia or
wolbachial remnants to be cleared by the worm and appear neg-
ative by immunohistology.
Dynamics of Reinfection
The increasing proportion of Wolbachia-positive worms after
9.5 months is driven partly by reinfection with doxycycline-
naive, Wolbachia-positive worms, and partly by the increased
mortality of Wolbachia-depleted and Wolbachia-negative
worms. These effects dilute the directly observable effect of dox-
ycycline treatment on wolbachial loads to a degree that depends
on when observations are made after treatment (Figure 2A).
Therapeutic Efﬁcacy of Doxycycline
The therapeutic efﬁcacy of doxycycline is deﬁned as the maxi-
mum proportional reduction in the percentage of adult female
O. volvulus positive for Wolbachia. This is not directly observ-
able because (1) data are not available from all participants, at
times when the minimum percentage of Wolbachia-positive
worms would be observed; (2) the pretreatment percentage
of Wolbachia-positive worms for each participant is estimated
from the model; and (3) some (approximately 3%)Wolbachia-
positive worms are missed by the estimated 97% sensitivity
(Table 2) of Wolbachia detection methods. The efﬁcacy esti-
mates depicted in Figures 3 and 4 indicate that efﬁcacy
is >91% on average, >95% in the majority of participants,
and that there is no statistically signiﬁcant difference among
treatment regimens. The model’s structural conﬁguration has
a negligible effect on efﬁcacy estimates (Supplementary
Figure 4).
Macroﬁlaricidal Activity
The estimated 2- to 3-year life expectancy of female worms de-
pleted of Wolbachia (Table 2) is 20%–30% of the average 8- to
12-year life expectancy [12] of Wolbachia-positive worms. This
reduced longevity drives the prolonged decline in the percent-
age of live O. volvulus, which troughs at approximately 50%, 2.5
Figure 2. Fitted and observed proportions of female Onchocerca volvulus by Wolbachia status and viability, against time since the start of doxycycline
treatment. The proportion of (live) Wolbachia-positive female worms is depicted in (A) and the proportion of (total) live female worms is depicted in (B ). In
each panel, the thick blue, green, and red lines denote, respectively, the marginal percentage of worms (ie, averaged over trial participants) receiving
doxycycline for 4, 5, or 6 weeks respectively. Solid and broken lines indicate doses of 100 mg and 200 mg, respectively. The thick solid gray line denotes
the marginal percentage of worms in placebo-treated and untreated control patients (Table 1). Thin lines, applying the same color scheme to indicate
different treatment regimens, represent ( posterior mean) individual patient trajectories. Variation among individual trajectories in the percentage of
(total) live worms and the percentage of (live) Wolbachia-positive worms is governed by the precision parameters υ1 and υ2 (Table 2), respectively.
Data points represent the observed data grouped (for presentation purposes only; the model is ﬁtted to the individual patient data) by follow-up times
(follow-up times disaggregated by month of follow-up are given in Supplementary Table 1) and plotted at the median follow-up time per group. The color of
the data points corresponds to the duration of treatment in the same manner as the model-predicted proportions. A treatment dose of 100 mg or 200 mg per
day is indicated by a circle or a triangle, respectively; data from untreated or placebo treated patients are indicated by (gray) squares. Vertical bars represent
exact (likelihood proﬁle) 95% conﬁdence intervals for the observed data. Note that data from different regimens collected at proximate times are very
similar, verifying that different treatment regimens are of approximately equivalent efﬁcacies (Figure 3). The progressive increase in the proportion of
live, Wolbachia-positive worms after 9.5 months is not due to recrudescence of the bacteria, but to both acquisition of new, drug-naive worms with a
full complement of bacteria, and increased mortality of treated worms.
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years after the start of treatment (Figure 2B). Despite the fact
that the directly observable maximum decline in the percentage
of live worms is just 30%, the reduction in longevity of adult
worms is considerable, illustrating that the true macroﬁlaricidal
activity of doxycycline is greater than can be detected using di-
rect methods of evaluation.
DISCUSSION
Quantiﬁcation of the antiﬁlarial effects of anti-Wolbachia ther-
apy has hitherto been restricted to outcomes, such as the per-
centage of Wolbachia-positive, negative, or dead O. volvulus,
measured at various times after treatment in clinical trials.
The dynamics of these outcomes, driven by post-treatment rein-
fection and the slow turnover of long-lived ﬁlarial populations,
precludes the use of traditional meta-analytical approaches to
assess antiﬁlarial activity. The model presented here overcomes
these problems by coupling the dynamics of doxycycline-
induced Wolbachia depletion with the ensuing antiﬁlarial ef-
fects. By ﬁtting the model to clinical trial data on theWolbachia
and viability status of female O. volvulus, we estimate that (1)
the efﬁcacy of doxycycline (the maximum proportional reduc-
tion in the percentage of adult female O. volvulus positive for
Wolbachia) therapy is >91% on average and >95% in the major-
ity of participants, irrespective of treatment regimen, and (2) the
macroﬁlaricidal effect of eliminating Wolbachia is a 70%–80%
reduction in parasite life span.
Accounting for the competing effects of chemotherapy and
post-treatment reinfection by drug-naive pathogens on directly
observable measures of therapeutic efﬁcacy is generally applica-
ble to clinical trials conducted in endemic settings. Rarely, at-
tempts have been made to restrict reinfection. For example,
household insecticidal control of triatomine vectors of Trypano-
soma cruzi was used to reduce reinfection during a trial of benz-
nidazole for Chagas disease [21]. More commonly, exogenous
reinfections are distinguished from endogenous infections (rep-
resentative of treatment failure) at the evaluation stage. For ex-
ample, molecular (genetic) analytical approaches are used to
identify post-treatment reinfections with the etiological agents
of duodenal ulcers [22], tuberculosis [23], malaria [24], and
Figure 3. The efﬁcacy of doxycycline in depleting Wolbachia from adult
female Onchocerca volvulus estimated for different drug regimens. Efﬁcacy
is deﬁned as the maximum proportional reduction in the percentage of
adult female O. volvulus positive for Wolbachia. The circles represent pos-
terior medians of the estimates for each of the 114 treated trial partici-
pants. These are overlaid with a box-and-whisker plot depicting the
interquartile range (IQR) of individual estimates (box) and extending to
1.5 × IQR (whiskers). The solid horizontal bar within the box depicts the
median of the individual efﬁcacy estimates. The solid horizontal bars be-
side the individual estimates represent the marginal efﬁcacy averaged over
all patients receiving a particular treatment regimen. The accompanying
error bars represent 95% Bayesian credible intervals (BCIs). The values
and BCIs of the marginal efﬁcacies are as follows: 100 mg daily for 5
weeks, 93% (89%–96%); 100 mg daily for 6 weeks, 93% (91%–95%);
200 mg daily for 4 weeks, 93% (88%–96%); 200 mg daily for 6 weeks,
91% (86%–94%).
Figure 4. The distribution of efﬁcacies estimated for individual patients
aggregated by treatment regimen. Efﬁcacy is deﬁned as the maximum pro-
portional reduction in the percentage of adult female Onchocerca volvulus
positive for Wolbachia. Efﬁcacy estimates represent posterior medians for
each of the 114 treated patients. The vertical dashed line is the median of
the individual estimates indicating that the efﬁcacy of doxycycline is > 95%
in the majority of patients.
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intestinal schistosomiasis [25]. Morphological characteristics
have been used to identify young, newly acquired O. volvulus,
permitting adjustment of the observed proportion of dead
worms by the number estimated to have been acquired after-
treatment and prior to evaluation [7]. However, this approach
does not address the further complication—particularly rele-
vant to the protracted population dynamics of ﬁlarial para-
sites—that observed outcomes are dependent not only on
treatment efﬁcacy but when after treatment observations are
made. Consequently, to permit simultaneous analysis of data
collected at different follow-up times and to account for the va-
garies of the epidemiological context, ﬁtting a population dy-
namics model able to capture the effects of reinfection on
outcome measures provides a powerful solution [26, 27].
The clinical trials from which the data are derived aimed to
demonstrate a statistically signiﬁcant difference between out-
comes in treated vs control participants. The modeling shows
that follow-up times with maximum statistical power to achieve
this aim depend on the outcome in question. For example, live
Wolbachia-positive O. volvulus (detectable by immunohistol-
ogy) are least abundant 9.5 months after the start of treatment,
whereas the corresponding ﬁgure for dead worms is 2.5 years
(100% percentage of live worms in Figure 2). The clinical trials
so far undertaken have included follow-up times that fall broad-
ly within these optimal time frames, depending on whether the
focus was on the doxycycline-induced depletion of Wolbachia
[9] or on the killing of adult worms [8, 10]. Data have also
been collected at less than optimal follow-up times. Here this
has proved serendipitous to estimating our model parameters
to an acceptable accuracy, highlighting that to parameterize
mathematical models, a broad range of follow-up times is
essential.
The 93% average efﬁcacy for patients receiving the 4-week
course of doxycycline (Figure 3), the shortest that has hitherto
been trialed (although a trial including a 3-week course of dox-
ycycline has recently been completed but not yet evaluated; see
http://isrctn.org/ISRCTN06010453), is impressive and above
the 90% empirical threshold for optimum antiﬁlarial effects
[2]. The absence of a statically signiﬁcant difference among
treatment regimens suggests that the 4-week course, as previ-
ously proposed [28], is sufﬁcient for anti-Wolbachia therapy.
Little substantive insight into the minimum therapeutically suf-
ﬁcient duration is possible here, as none of the regimens precip-
itate systematically lower percentages of Wolbachia-positive
worms in treated participants. However, evidence from a
small number of individuals who dropped out of treatment
after 2 weeks suggests that this duration is insufﬁcient. There-
fore, it is reasonable to conclude that the minimum therapeuti-
cally sufﬁcient course of doxycycline alone is between 2 and 4
weeks. Ongoing work by the Anti-Wolbachia Consortium
(A•WOL, http://www.a-wol.net/) has shown in animal models
and clinical trials that anti-Wolbachia drug combinations can
markedly reduce treatment duration [29].
Doxycycline is currently the best option for treatment of on-
chocerciasis or lymphatic ﬁlariasis in patients attending clinical
settings [6]. Doxycycline is the only available safe and effective
curative therapy for onchocerciasis. For lymphatic ﬁlariasis,
doxycycline does not have the side effects associated with the
rapid microﬁlaricidal activity of diethylcarbamazine and ame-
liorates morbidity [2, 30]. Doxycycline has been considered in-
compatible with treatment in community settings because of
perceived issues of compliance with the treatment course,
contraindications in pregnant/breastfeeding women and chil-
dren aged <8 years, and inadequate cost–beneﬁt ratios [2, 6].
However, results from a trialed community-directed treatment
approach suggested that high levels of coverage and compliance
with 6 weeks of doxycycline could be achieved [31], with long-
term reductions in microﬁlaridermia that are sustained for at
least 4 years after delivery [32]. Moreover, A•WOL aims to
ﬁnd new anti-Wolbachia treatment regimens, including novel
antimicrobial agents and alternative combinations of existing
antimicrobials that are efﬁcacious over a shorter duration and
may be safe for currently excluded groups. It is thus envisaged
that anti-Wolbachia therapy will in the future have a wider scope
of application [29].
There are 3 main scenarios in which anti-Wolbachia therapy
could be administered to populations on a “test and treat” basis.
First, the delivery of community-directed treatment with iver-
mectin is impeded in areas where loiasis is coendemic with on-
chocerciasis and/or lymphatic ﬁlariasis because of the risk of
severe adverse events [33]. This may hinder progress toward
the World Health Organization’s 2020 control and elimination
goals [34]. Anti-Wolbachia therapy offers a viable alternative in
such areas because Loa loa (the causal agent of loiasis) is one of
the few ﬁlarial species withoutWolbachia and so it is unaffected
by treatment [1, 2]. Second, in those foci where elimination is
deemed achievable, and transmission has been suppressed but
not yet interrupted, targeted anti-Wolbachia therapy may be
used to “mop up” residual infections [35, 36]. Third, anti-
Wolbachia therapy would provide an invaluable backup ap-
proach in regions where suboptimal responses to ivermectin
have been reported [37, 38].
Existing ﬁlariasis transmission models need to capture the ef-
fects of anti-Wolbachia therapy on ﬁlarial population dynamics
to guide and assess the effectiveness and cost-effectiveness of
new anti-Wolbachia intervention strategies. The presented
model is designed to be generalizable to any anti-Wolbachia
therapy of a human ﬁlariasis. Once linked with transmission
dynamics models, it will inform the use of anti-Wolbachia ther-
apy as an alternative and/or complementary strategy to help the
ongoing onchocerciasis and lymphatic ﬁlariasis control and
elimination programs, particularly in epidemiological settings
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where current strategies are deemed insufﬁcient to achieve the
2020 goals [34].
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